Development and potential clinical uses of human prolactin receptor antagonists

Endocrine Reviews

Volumn 26, Issue 3, 2005, Pages 400-422

  Goffin, Vincent ^a,b   Bernichtein, Sophie ^a,b   Touraine, Philippe ^a,b,c   Kelly, Paul A ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PROTEIN; BROMOCRIPTINE; CABERGOLINE; DOCETAXEL; DOPAMINE RECEPTOR STIMULATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GUANINE NUCLEOTIDE BINDING PROTEIN; HORMONE RECEPTOR BLOCKING AGENT; PERGOLIDE; PROLACTIN; PROLACTIN RECEPTOR; PROLACTIN RECEPTOR ANTAGONIST; QUINAGOLIDE; STAT5 PROTEIN; TRANSCRIPTION FACTOR PIT 1; UNCLASSIFIED DRUG;

AUTOCRINE EFFECT; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL SURVIVAL; CLINICAL TRIAL; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HYPERPROLACTINEMIA; MICROADENOMA; NONHUMAN; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; PROLACTIN SYNTHESIS; PROLACTINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR BIOPSY; TUMOR GROWTH;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, PROLACTIN;

EID: 18844447250     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2004-0016     Document Type: Review

References (153)

1. Goffin V, Shiverick KT, Kelly PA, Martial JA 1996 Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals. Endocr Rev 17:385-410
2. Nicoll CS, Mayer GL, Russell SM 1986 Structural features of prolactins and growth hormones that can be related to their biological properties. Endocr Rev 7:169-203
3. Miller WL, Eberhardt NL 1983 Structure and evolution of the growth hormone gene family. Endocr Rev 4:97-130
4. Horseman ND, Yu-Lee LY 1994 Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines. Endocr Rev 15:627-649
5. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA 1998 Prolactin and its receptor: actions, signal transduction pathways and phenotypes observed in prolactin receptor knockout mice. Endocr Rev 19:225-268
6. Boutin JM, Jolicoeur C, Okamura H, Gagnon J, Edery M, Shirota M, Banville D, Dusanter-Fourt I, Djiane J, Kelly PA 1988 Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family. Cell 53:69-77
7. Kelly PA, Djiane J, Banville D, Ali S, Edery M, Rozakis M 1991 The growth hormone/prolactin receptor gene family. In: Maclean N, ed. Oxford surveys on eukaryotic genes. London: Oxford University Press; 29-50
8. Wells JA, De Vos AM 1996 Hematopoietic receptor complexes. Annu Rev Biochem 65:609-634
9. De Vos AM, Ultsch M, Kossiakoff AA 1992 Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255:306-312
10. Somers W, Ultsch M, De Vos AM, Kossiakoff AA 1994 The x-ray structure of the growth hormone-prolactin receptor complex. Nature 372:478-481
11. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA 1996 Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 273:464-471
12. Elkins PA, Christinger HW, Sandowski Y, Sakal E, Gertler A, De Vos AM, Kossiakoff AA 2000 Ternary complex between placental lactogen and the extracellular domain of the prolactin receptor. Nat Struct Biol 7:808-815
13. Clevenger CV, Furth PA, Hankinson SE, Schuler LA 2003 The role of prolactin in mammary carcinoma. Endocr Rev 24:1-27
14. Smirnova OV, Bogorad RL 2004 Short forms of membrane receptors: generation and role in hormonal signal transduction. Biochemistry (Mosc) 69:351-363
15. Binart N, Imbert-Bollore P, Baran N, Viglietta C, Kelly PA 2003 A short form of the prolactin (PRL) receptor is able to rescue mammopoiesis in heterozygous PRL receptor mice. Mol Endocrinol 17:1066-1074
16. Clevenger CV, Freier DO, Kline JB 1998 Prolactin receptor signal transduction in cells of the immune system. J Endocrinol 157:187-197
17. Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff E, Dorshkind K 1997 Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 16:6926-6935
18. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas BK, Buteau H, Edery M, Brousse N, Babinet C, Binart N, Kelly PA 1997 Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 11:167-178
19. Molitch ME 2002 Medical management of prolactin-secreting pituitary adenomas. Pituitary 5:55-65
20. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW 1996 Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639-669
21. Arafah BM, Nasrallah MP 2001 Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer 8:287-305
22. Freeman ME, Kanyicska B, Lerant A, Nagy G 2000 Prolactin: structure, function, and regulation of secretion. Physiol Rev 80:1523-1631
23. Andersen B, Rosenfeld MG 2001 POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease. Endocr Rev 22:2-35
24. Zargar AH, Masoodi SR, Laway BA, Shah NA, Salahudin M 1997 Familial puerperal alactogenesis: possibility of a genetically transmitted isolated prolactin deficiency. Br J Obstet Gynaecol 104:629-631
25. Touraine P, Kelly PA 1997 Physiologie de la prolactine et mécanismes d'action. In: Mauvais-Jarvis P, Schaison G, Touraine P, eds. Médecine de la reproduction. Paris: Flammarion; 115-136
26. Vera-Lastra O, Jara LJ, Espinoza LR 2002 Prolactin and autoimmunity. Autoimmun Rev 1:360-364
27. Walker SE 2001 Treatment of systemic lupus erythematosus with bromocriptine. Lupus 10:197-202
28. Vonderhaar BK 1999 Prolactin involvement in breast cancer. Endocr Relat Cancer 6:389-404
29. Vonderhaar BK 1998 Prolactin: the forgotten hormone of human breast cancer. Pharmacol Ther 79:169-178
30. Llovera M, Pichard C, Bernichtein S, Jeay S, Touraine P, Kelly PA, Goffin V 2000 Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 19:4695-4705
31. Goffin V, Touraine P, Pichard C, Bernichtein S, Kelly PA 1999 Should prolactin be reconsidered as a therapeutic target in human breast cancer? Mol Cell Endocrinol 151:79-87
32. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V 2000 Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141:118-126
33. Janssen T, Darro F, Petein M, Raviv G, Pasteels JL, Kiss R, Schulman CC 1996 In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer 77:144-149
34. Nandi S, Guzman RC, Yang J 1995 Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 92:3650-3657
35. Ben Jonathan N, Liby K, McFarland M, Zinger M 2002 Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 13:245-250
36. Welsch CW, Nagasawa H 1977 Prolactin and murine mammary tumorigenesis: a review. Cancer Res 37:951-963
37. Wennbo H, Kindblom J, Isaksson OG, Tornell J 1997 Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 138:4410-4415
38. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J 1997 Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 100:2744-2751
39. Vomachka AJ, Pratt SL, Lockefeer JA, Horseman ND 2000 Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene 19:1077-1084
40. Robertson FG, Harris J, Naylor MJ, Oakes SR, Kindblom J, Dillner K, Wennbo H, Tornell J, Kelly PA, Green J, Ormandy CJ 2003 Prostate development and carcinogenesis in prolactin receptor knockout mice. Endocrinology 144:3196-3205
41. Liby K, Neltner B, Mohamet L, Menchen L, Ben Jonathan N 2003 Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Res Treat 79:241-252
42. Xu X, Kreye E, Kuo CB, Walker AM 2001 A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when du145 human prostate cancer cells were grown in nude mice. Cancer Res 61:6098-6104
43. Ahonen TJ, Harkonen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT 1999 Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology 140:5412-5421
44. Harris J, Stanford PM, Oakes SR, Ormandy CJ 2004 Prolactin and the prolactin receptor: new targets of an old hormone. Ann Med 36:414-425
45. Biswas R, Vonderhaar BK 1987 Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long-term tissue culture. Cancer Res 47:3509-3514
46. Schroeder MD, Symowicz J, Schuler LA 2002 PRL modulates cell cycle regulators in mammary tumor epithelial cells. Mol Endocrinol 16:45-57
47. Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE 1999 A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin Cancer Res 5:3583-3593
48. Beck MT, Peirce SK, Chen WY 2002 Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene 21:5047-5055
49. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM 2004 Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer 91:305-311
50. Ruffion A, Al Sakkaf KA, Brown BL, Eaton CL, Hamdy FC, Dobson PR 2003 The survival effect of prolactin on PC3 prostate cancer cells. Eur Urol 43:301-308
51. Maus MV, Reilly SC, Clevenger CV 1999 Prolactin as a chemoattractant for human breast carcinoma. Endocrinology 140:5447-5450
52. Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, Weiner RI, Martial JA 1999 Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: novel mechanism for the regulation of angiogenesis. Proc Natl Acad Sci USA 96:1246-1251
53. Harkonen P 2003 Paracrine prolactin may cause prostatic problems. Endocrinology 144:2266-2268
54. Kindblom J, Dillner K, Ling C, Tornell J, Wennbo H 2002 Progressive prostate hyperplasia in adult prolactin transgenic mice is not dependent on elevated serum androgen levels. Prostate 53:24-33
55. Fuh G, Wells JA 1995 Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem 270:13133-13137
56. Nevalainen MT, Valve EM, Ingleton PM, Harkonen PL 1996 Expression and hormone regulation of prolactin receptors in rat dorsal and lateral prostate. Endocrinology 137:3078-3088
57. Ormandy CJ, Hall RE, Manning DL, Robertson JF, Blamey RW, Kelly PA, Nicholson RI, Sutherland RL 1997 Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab 82:3692-3699
58. Rose DP, Pruitt BT 1981 Plasma prolactin levels in patients with breast cancer. Cancer 48:2687-2691
59. Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, Hayward JL, Millis RR 1992 Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol 21:214-221
60. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE 2000 A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 9:575-579
61. Ingram DM, Nottage EM, Roberts AN 1990 Prolactin and breast cancer risk. Med J Aust 153:469-473
62. Secreto G, Recchione C, Cavalleri A, Miraglia M, Dati V 1983 Circulating levels of testosterone, 17 β-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients. Br J Cancer 47:269-275
63. Bernstein L, Ross RK, Pike MC, Brown JB, Henderson BE 1990 Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls. Br J Cancer 61:298-302
64. Meyer F, Brown JB, Morrison AS, MacMahon B 1986 Endogenous sex hormones, prolactin, and breast cancer in premenopausal women. J Natl Cancer Inst 77:613-616
65. Love RR, Rose DR, Surawicz TS, Newcomb PA 1991 Prolactin and growth hormone levels in premenopausal women with breast cancer and healthy women with a strong family history of breast cancer. Cancer 68:1401-1405
66. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE 1999 Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91:629-634
67. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE 2004 Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 64:6814-6819
68. Stattin P, Rinaldi S, Stenman UH, Riboli E, Hallmans G, Bergh A, Kaaks R 2001 Plasma prolactin and prostate cancer risk: a prospective study. Int J Cancer 92:463-465
69. Colao A, Vitale G, Di Sarno A, Spiezia S, Guerra E, Ciccaielli A, Lombardi G 2004 Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. J Clin Endocrinol Metab 89:2770-2775
70. Fritze D, Queisser W, Schmid H, Kaufmann M, Massner B, Westerhausen M, Schmidt R, Edler L, Abel U 1986 Prospective randomized trial concerning hyper- and normoprolactinemia and the use of bromoergocryptine in patients with metastatic breast cancer. Onkologie 9:305-312
71. Bonneterre J, Mauriac L, Weber B, Roche H, Fargeot P, Tubiana-Hulin M, Sevin M, Chollet P, Cappelaere P 1988 Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial. Eur J Cancer Clin Oncol 24:1851-1853
72. Horti J, Figg WD, Weinberger B, Kohler D, Sartor O 1998 A phase II study of bromocriptine in patients with androgen-independent prostate cancer. Oncol Rep 5:893-896
73. Lissoni P, Bucovec R, Malugani F, Ardizzoia A, Villa S, Gardani GS, Vaghi M, Tancini G 2002 A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines. Anticancer Res 22:1131-1134
74. Clevenger CV, Plank TL 1997 Prolactin as an autocrine/paracrine factor in breast cancer. J Mammary Gland Biol Neoplasia 2:59-68
75. Das R, Vonderhaar BK 1997 Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia 2:29-39
76. Ginsburg E, Vonderhaar BK 1995 Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 55:2591-2595
77. Brockman JL, Schroeder MD, Schuler LA 2002 PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol Endocrinol 16:774-784
78. Clevenger CV, Chang WP, Ngo W, Pasha TM, Montone KT, Tomaszewski JE 1995 Expression of prolactin and prolactin receptor in human breast carcinoma. Am J Pathol 146:695-705
79. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV 1997 Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 138:5555-5560
80. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F, Kelly PA 1998 Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors vs. normal breast tissues. J Clin Endocrinol Metab 83:667-674
81. Mertani HC, Garcia-Caballero T, Lambert A, Gerard F, Palayer C, Boulin JM, Vonderhaar BK, Waters MJ, Lobie PE, Morel G 1998 Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer 79:202-211
82. Bertucci F, Nasser V, Granjeaud S, Eisinger F, Adelaide J, Tagett R, Loriod B, Giaconia A, Benziane A, Devilard E, Jacquemier J, Viens P, Nguyen C, Birnbaum D, Houlgatte R 2002 Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Hum Mol Genet 11:863-872
83. Meng J, Tsai-Morris CH, Dufau ML 2004 Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma. Cancer Res 64:5677-5682
84. Gutzman JH, Miller KK, Schuler LA 2004 Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor α and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J Steroid Biochem Mol Biol 88:69-77
85. Yamauchi T, Yamauchi N, Ueki K, Sugiyama T, Waki H, Miki H, Tobe K, Matsuda S, Tsushima T, Yamamoto T, Fujita T, Taketani Y, Fukayama M, Kimura S, Yazaki Y, Nagai R, Kadowaki T 2000 Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. J Biol Chem 275:33937-33944
86. Nevalainen MT, Valve EM, Ingleton PM, Nunni M, Martikainen PM, Harkonen PL 1997 Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 99:618-627
87. Leav I, Merk FB, Lee KF, Loda M, Mandoki M, McNeal JE, Ho SM 1999 Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol 154:863-870
88. Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EL, Zhang Y, Nurmi M, Singh B, Martikainen PM, Nevalainen MT 2004 Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 64:4774-4782
89. Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nunni M, Alanen K, Rui H, Nevalainen MT 2003 Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 278:27287-27292
90. Baudhuin A, Manfroid I, Van De Weerdt C, Martial JA, Muller M 2002 Transcription of the human prolactin gene in mammary cells. Ann NY Acad Sci 973:454-458
91. Shaw-Bruha CM, Pirrucello SJ, Shull JD 1997 Expression of the prolactin gene in normal and neoplastic human breast tissues and human mammary cell lines: promoter usage and alternative mRNA splicing. Breast Cancer Res Treat 44:243-253
92. Manfroid I, Van De Weerdt C, Baudhuin A, Martial JA, Muller M 2005 EGF stimulates Pit-1 independent transcription of the human prolactin pituitary promoter in human breast cancer SK-BR-3 cells through its proximal AP-1 response element. Mol Cell Endocrinol 229:127-139
93. Naylor MJ, Lockefeer JA, Horseman ND, Ormandy CJ 2003 Prolactin regulates mammary epithelial cell proliferation via autocrine/paracrine mechanism. Endocrine 20:111-114
94. Kindblom J, Dillner K, Sahlin L, Robertson F, Ormandy C, Tornell J, Wennbo H 2003 Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 144:2269-2278
95. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA 2003 Prolactin induces ERα-positive and ERα-negative mammary cancer in transgenic mice. Oncogene 22:4664-4674
96. Llovera M, Touraine P, Kelly PA, Goffin V 2000 Involvement of prolactin in breast cancer: redefining the molecular targets. Exp Gerontol 35:41-51
97. Zinger M, McFarland M, Ben Jonathan N 2003 Prolactin expression and secretion by human breast glandular and adipose tissue explants. J Clin Endocrinol Metab 88:689-696
98. Molitch ME 2003 Dopamine resistance of prolactinomas. Pituitary 6:19-27
99. Barlier A, Pellegrini-Bouiller I, Caccavelli L, Gunz G, Morange-Ramos I, Jaquet P, Enjalbert A1997 Abnormal transduction mechanisms in pituitary adenomas. Horm Res 47:227-234
100. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA 1992 Rational design of potent antagonists to the human growth hormone receptor. Science 256:1677-1680
101. Fuh G, Colosi P, Wood WI, Wells JA 1993 Mechanism-based design of prolactin receptor antagonists. J Biol Chem 268:5376-5381
102. Cunningham BC, Wells JA 1991 Rational design of receptor-specific variants of human growth hormone. Proc Natl Acad Sci USA 88:3407-3411
103. Frank SJ 2002 Minireview: receptor dimerization in GH and erythropoietin action. It takes two to tango, but how? Endocrinology 143:2-10
104. Biener E, Martin C, Daniel N, Frank SJ, Centonze VE, Herman B, Djiane J, Gertler A 2003 Ovine placental lactogen-induced heterodimerization of ovine growth hormone and prolactin receptors in living cells is demonstrated by fluorescence resonance energy transfer microscopy and leads to prolonged phosphorylation of signal transducer and activator of transcription (STAT)1 and STAT3. Endocrinology 144:3532-3540
105. Kossiakoff AA, Somers W, Ultsch M, Andow K, Muller YA, De Vos AM 1994 Comparison of the intermediate complexes of human growth hormone bound to the human growth hormone and prolactin receptors. Protein Sci 3:1697-1705
106. Sivaprasad U, Canfield JM, Brooks CL 2004 Mechanism for ordered receptor binding by human prolactin. Biochemistry 43:13755-13765
107. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646
108. Clackson T, Ultsch MH, Wells JA, De Vos AM 1998 Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. J Mol Biol 277:1111-1128
109. Goffin V, Struman I, Mainfroid V, Kinet S, Martial JA 1994 Evidence for a second receptor binding site on human prolactin. J Biol Chem 269:32598-32606
110. Helman D, Staten NR, Grosclaude J, Daniel N, Nespoulous C, Djiane J, Gertler A 1998 Novel recombinant analogues of bovine placental lactogen. G133K and G133R provide a tool to understand the difference between the action of prolactin and growth hormone receptors. J Biol Chem 273:16067-16074
111. Wells JA 1994 Structural and functional basis for hormone binding and receptor oligomerization. Curr Opin Cell Biol 6:163-173
112. Wells JA 1996 Binding in the growth hormone receptor complex. Proc Natl Acad Sci USA 93:1-6
113. Goffin V, Kinet S, Ferrag F, Binart N, Martial JA, Kelly PA 1996 Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. J Biol Chem 271:16573-16579
114. Dattani MT, Hindmarsh PC, Brook CD, Robinson IF, Kopchick JJ, Marshall NJ 1995 G120R, a human growth hormone antagonist, shows zinc-dependent agonist and antagonist activity on Nb2 cells. J Biol Chem 270:9222-9226
115. Mode A, Tollet P, Wells T, Carmignac DF, Clark RG, Chen WY, Kopchick JJ, Robinson IC 1996 The human growth hormone (hGH) antagonist G120RHGH does not antagonize GH in the rat, but has paradoxical agonist activity, probably via the prolactin receptor. Endocrinology 137:447-454
116. Goffin V, Bernichtein S, Carrière O, Bennett WF, Kopchick JJ, Kelly PA 1999 The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology 140:3853-3856
117. Ramamoorthy P, Sticca R, Wagner TE, Chen WY 2001 In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells. Int J Oncol 18:25-32
118. Cataldo L, Chen NY, Yuan Q, Li W, Ramamoorthy P, Wagner TE, Sticca RP, Chen WY 2000 Inhibition of oncogene STAT5 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells. Int J Oncol 17:1179-1185
119. Bernichtein S, Jeay S, Vaudry R, Kelly PA, Goffin V 2003 New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity. Endocrine 20:177-190
120. Bernichtein S, Kinet S, Jeay S, Madern M, Martial JA, Kelly PA, Goffin V 2001 S179D-hPRL, a pseudo-phosphorylated human prolactin analog, is an agonist and not an antagonist. Endocrinology 142:3950-3963
121. Peirce SK, Chen WY 2004 Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice. Oncogene 23:1248-1255
122. Kaulsay KK, Zhu T, Bennett W, Lee K, Lobie PE 2001 The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology 142:767-777
123. Bernichtein S, Kayser C, Dillner K, Moulin S, Kopchick JJ, Martial JA, Norstedt G, Isaksson O, Kelly PA, Goffin V 2003 Development of pure prolactin receptor antagonists. J Biol Chem 278:35988-35999
124. Kinet S, Bernichtein S, Kelly PA, Martial JA, Goffin V 1999 Biological properties of human prolactin analogs depend not only on global hormone affinity, but also on the relative affinities of both receptor binding sites. J Biol Chem 274:26033-26043
125. Goffin V, Norman M, Martial JA1992 Alanine-scanning mutagenesis of human prolactin: importance of the 58-74 region for bioactivity. Mol Endocrinol 6:1381-1392
126. Cunningham BC, Bass S, Fuh G, Wells JA 1990 Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science 250:1709-1712
127. Sun Z, Li PS, Dannies PS, Lee JC 1996 Properties of human prolactin (PRL) and H27A-PRL, a mutant that does not bind Zn++. Mol Endocrinol 10:265-271
128. Chen TJ, Kuo CB, Tsai KF, Liu JW, Chen DY, Walker AM 1998 Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology 139:609-616
129. Sinha YN 1995 Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 16:354-369
130. Wang YF, Liu JW, Mamidi M, Walker AM 1996 Identification of the major site of rat prolactin phosphorylation as serine 177. J Biol Chem 271:2462-2469
131. Coss D, Kuo CB, Yang L, Ingleton P, Luben R, Walker AM 1999 Dissociation of Janus kinase 2 and signal transducer and activator of transcription 5 activation after treatment of Nb2 cells with a molecular mimic of phosphorylated prolactin. Endocrinology 140:5087-5094
132. Wu W, Coss D, Lorenson MY, Kuo CB, Xu X, Walker AM 2003 Different biological effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin involve different signaling pathways. Biochemistry 42:7561-7570
133. Schroeder MD, Brockman JL, Walker AM, Schuler LA 2003 Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL. Endocrinology 144:5300-5307
134. Bridges RS, Rigero BA, Byrnes EM, Yang L, Walker AM 2001 Central infusions of the recombinant human prolactin receptor antagonist, S179D-PRL, delay the onset of maternal behavior in steroid-primed, nulliparous female rats. Endocrinology 142:730-739
135. Yang L, Kuo CB, Liu Y, Coss D, Xu X, Chen C, Oster-Granite ML, Walker AM 2001 Administration of unmodified prolactin (U-PRL) and a molecular mimic of phosphorylated prolactin (PP-PRL) during rat pregnancy provides evidence that the U-PRL:PP-PRL ratio is crucial to the normal development of pup tissues. J Endocrinol 168:227-238
136. Kuo CB, Wu W, Xu X, Yang L, Chen C, Coss D, Birdsall B, Nassen D, Walker AM 2002 Pseudophosphorylated prolactin (S179D PRL) inhibits growth and promotes β-casein gene expression in the rat mammary gland. Cell Tissue Res 309:429-437
137. Coss D, Yang L, Kuo CB, Xu X, Luben RA, Walker AM 2000 Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol 279:1216-1225
138. Keeler C, Dannies PS, Hodsdon ME 2003 The tertiary structure and backbone dynamics of human prolactin. J Mol Biol 328:1105-1121
139. Bernichtein S, Jomain JB, Kelly PA, Goffin V 2003 The N-terminus of human prolactin modulates its biological properties. Mol Cell Endocrinol 208:11-21
140. Kline JB, Clevenger CV 2001 Identification and characterization of the prolactin-binding protein in human serum and milk. J Biol Chem 276:24760-24766
141. Chen WY, Chen NY, Yun J, Wagner TE, Kopchick JJ 1994 In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. J Biol Chem 269:15892-15897
142. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KK 2001 Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 86:1716-1723
143. van Neck JW, Dits NF, Cingel V, Hoppenbrouwers IA, Drop SL, Flyvbjerg A 2000 Dose-response effects of a new growth hormone receptor antagonist (B2036-PEG) on circulating, hepatic and renal expression of the growth hormone/insulin-like growth factor system in adult mice. J Endocrinol 167:295-303
144. McCutcheon IE, Flyvbjerg A, Hill H, Li J, Bennett WF, Scarlett JA, Friend KE 2001 Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 94:487-492
145. Craig Jordan V, Morrow M 1999 Tamoxifen, haloxifen and the prevention of breast cancer. Endocr Rev 20:253-278
146. Brueggemeier RW, Hackett JC, Diaz-Cruz ES 2005 Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 26:331-345
147. Fischer OM, Streit S, Hart S, Ullrich A 2003 Beyond Herceptin and Gleevec. Curr Opin Chem Biol 7:490-495
148. Labrie F, Bélanger A, Candas B, Cusan L, Gomez J, Labrie C, Luu-The V, Simard J 2005 Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 26:361-379
149. Bertucci F, Viens P, Hingamp P, Nasser V, Houlgatte R, Birnbaum D 2003 Breast cancer revisited using DNA array-based gene expression profiling. Int J Cancer 103:565-571
150. Jin L, Qian X, Kulig E, Scheithauer BW, Calle-Rodrigue R, Abboud C, Davis DH, Kovacs K, Lloyd RV 1997 Prolactin receptor messenger ribonucleic acid in normal and neoplastic human pituitary tissues. J Clin Endocrinol Metab 82:963-968
151. Schuff KG, Hentges ST, Kelly MA, Binart N, Kelly PA, luvone PM, Asa SL, Low MJ 2002 Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. J Clin Invest 110:973-981
152. Harris M 2004 Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5:292-302
153. Chen NY, Holle L, Li W, Peirce SK, Beck MT, Chen WY 2002 In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R. Int J Oncol 20:813-818